Distinguishing predictive and prognostic markers in patients with cancer requires adequate control groups and randomization such as those applied in prospective clinical trials. In order to identify factors predictive of sensitivity to taxane based regimens in patients with breast cancer, we analysed immunohistochemical markers in primary tumors of patients randomized to a taxane-based or a taxane-free adjuvant regimen. Our results show that microtubule-associated parameters such as tau protein or tubulin III isotype are prognostic in all patients, irrespective of the type of treatment received. We also found that P53 and Ki67 were independent prognostic factors in this patient population. These immunohistochemical markers can contribute to identify patients with a high risk of disease recurrence.
Introduction
Adjuvant polychemotherapy for women with early stage breast cancer has meaningfully improved disease free and overall survival (1). While anthracyclinebased chemotherapy has produced a modest improvement in DFS and OS over CMF (cyclophosphamide/methotrexate/fluorouracil) polychemotherapy regimens,(1) this benefit appears to be largely confined to the subset of patients with amplification of the erb-B2/neu or topoisomerase II alpha genes or overexpression of the corresponding proteins (2) (3) (4) (5) (6) . The microtubule stabilizing taxanes, paclitaxel and docetaxel, are among the most active single agents in women with advanced breast cancer (7) . Because taxanes exhibit incomplete cross-resistance with anthracyclines, and adjuvant anthracycline chemotherapy still leaves considerable residual risk of disease recurrence and death from breast cancer, multiple trials are addressing the value of incorporating taxanes, either sequentially or in combination with anthracyclines, in an effort to improve outcomes (8, 9) . The BCIRG 001 trial compared the standard fluorouracil-doxorubicin-cyclophosphamide (FAC) regimen to docetaxel-doxorubicin-cyclophosphamide (TAC) regimen as adjuvant chemotherapy in 1,491 patients with axillary node positive breast cancer. With a median follow-up of 55 months, a prospectively defined and event-triggered analysis showed that TAC was significantly superior to FAC, both in terms of disease-free survival (75% vs. 68% at 5 years) and in overall survival (87% vs. 81% at 5 years) (10) .
Evaluation within randomized trials is required to distinguish the predictive value of a marker (its relationship to outcome specifically attributable to a given intervention) from its prognostic value (the relationship to outcome irrespective of treatment) (11) .
Materials and Methods

Study design
In 1997, the Breast Cancer International Research Group began a phase 3 trial to compare the docetaxel-containing regimen TAC with a regimen of FAC as adjuvant treatment for women with operable node-positive breast cancer. In this multicenter, registration study, randomization was stratified according to institution and number of involved axillary lymph nodes per patient (one to three vs. four or more). On day 1 of each of six 21-day cycles, eligible patients received either TAC (50 mg of doxorubicin per square meter of body-surface area, 500 mg of cyclophosphamide per square meter and 75 mg of docetaxel per square meter) or FAC (50 mg of doxorubicin per square meter, 500 mg of fluorouracil per square meter and 500 mg of cyclophosphamide per square meter).
The primary end point was disease-free survival, defined as the time from randomization to the date of a clinical relapse (with histopathological confirmation or radiological evidence of tumor recurrence), a second cancer (with the exceptions of skin cancer other than melanoma, ductal or lobular carcinoma in situ of the breast, or in situ carcinoma of the cervix), or death, whichever occurred first; overall survival was a secondary endpoint. The protocol defined centralized assessment of tumor tissue for immunohistochemical assessment of biological parameters.
Immunohistochemistry
As per the study protocol and with prospective patient consent, slides containing pathologic material and a representative formalin fixed paraffin block from the primary tumor were requested from each patient's primary institution for central review and
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Statistical analysis
The aim of this biological study was to identify biological prognostic and/or predictive factors in a large series of patients receiving adjuvant therapy for node positive breast cancer. Among the 1,491 randomized patients, a total of 141 (9.5%) had no data on any of the main 16 tumor markers as primary tumor samples were unavailable for analysis. These 141 patients are excluded, leaving a total of 1,350
patients for the present analysis. Immunohistochemical parameters were analyzed as variables dichotomized at the median value observed in the population. Her2 status was dichotomized as positive or negative. The interaction test between each parameter and treatment arm was performed by testing the logarithm of the ratio of two hazard ratios.
Survival curves and probabilities were estimated using the Kaplan-Meier technique.
Differences between survival curves were assessed using the log-rank test. The Cox proportional hazards regression model was used for both univariate and multivariate analyses of survival. For the analysis of prognostic factors for survival analysis the proportionality assumption was checked for each of the variables under study by testing the dependency of their hazard ratio over time.
Research. arms and tumor markers were included in the analysis to identify potential effect modification. In the absence of interaction, exploratory analyses on treatment subgroups were performed. As a final step, a boot-strap analysis (20) with resubstitution of all individual samples was performed to confirm the independent parameters identified in the multivariate analyses or the exploratory analyses.
Results
Patient and tumor marker characteristics, patient outcome
Patient characteristics for the 1,350 patients included in the immunohistochemical analysis are presented in Table 1 . Data regarding the 9% of patients not included in this analysis were not available. The tumor marker characteristics are shown in Table   2 and 
Correlation of tumor markers with disease-free survival
In univariate analyses, treatment arm, tumor size (> 2.3 cm), mixed histology, estrogen receptor expression < 80% (cut-off value chosen due to the median value in the entire cohort), progesterone receptor expression < 80%, histological grade = 3, presence of extranodal disease, more than 2 involved axillary lymph nodes, high Ki-67 expression, high P53 expression, low MUC1 expression, high tubulin III, low levels of tau protein and high glu tubulin were significantly associated with shorter DFS (Table 3 ). There were no significant interaction between the expression level of any of the markers and the effect of treatment arm on disease-free survival.
In multivariate analysis, treatment arm, estrogen and progesterone receptors, number of involved nodes, Ki-67 and tau protein expression were independently associated with DFS (Table 5 ). These parameters were confirmed in the bootstrap analysis. In addition, the first order interaction between treatment arms, Ki-67 and tau protein expression were assessed using a Cox model. There were no significant interactions (ratio of hazard ratios for interaction treatment arms and Ki 
Correlation of tumor markers with overall survival
In univariate analyses, tumor size (> 2.3 cm), mixed histology, estrogen receptor expression < 80%, progesterone receptor expression < 80%, histological grade = 3, more than 2 involved axillary lymph nodes, high Ki-67 expression, high P53 expression, low BCL-2 expression, high BCL-XL, HER2 positivity, high tubulin III, low levels of tau protein and high glu tubulin were significantly associated with shorter OS (Table 4 ). There were no significant interaction between the expression level of any of the markers and the effect of treatment arm on overall survival.
In multivariate analysis, estrogen and progesterone receptors, number of nodes, P53, tubulin III and MIB-1 protein expression were independently associated with OS.
These parameters were confirmed in the bootstrap analysis. In addition, the first order interaction between treatment arms and P53 or Ki-67 or tubulin III protein expression were assessed through a Cox model. There were were no significant 
Discussion
The BCIRG001 study was a pivotal trial demonstrating the benefit of incorporating a taxane into adjuvant breast cancer polychemotherapy (10) . However, the substitution of docetaxel for fluorouracil increased toxicities, and not all patients remained disease-free. Consequently, it was our objective to determine which patients are most likely to benefit from adjuvant therapy with docetaxel. The identification of such molecular predictive factors is, however, complex because most markers correlated with outcome most frequently are prognostic rather than predictive (i.e. related to prognosis only in the setting of treatment with a specific intervention), (11, 21) and the mechanistic determinants of docetaxel response are poorly understood. Evaluation within the context of a randomized trial, such as BCIRG 001, is required to distinguish between prognostic and predictive value of a given biomarker.
In this immunohistochemical study, Ki-67 protein was found to be independently associated both with disease-free survival and overall survival. Tau protein was associated with disease-free survival, while p53 and tubulin III were associated with overall survival, even when taking into account classical factors such as hormone receptors, tumor size, extent of nodal involvement or mitotic grade. However these correlations were found both in patients receiving TAC or FAC, and interaction testing revealed no qualitative differences within treatment subgroups, indicating that these biological parameters were not predictive of sensitivity to either regimen.
Ki-67 is correlated with proliferation and has been shown to be correlated with the prognosis of breast cancer patients in several settings, including node-negative disease and in metastatic patients (22) (23) (24) (25) . Ki-67 correlates with the growth fraction
Research. in the group with the overall worst prognosis. Low tau expression levels could therefore be correlated both with a higher pathological response rate and a worse overall prognosis in this setting. Another hypothesis is the existence of a qualitative difference between docetaxel and paclitaxel, which is unlikely since the NSABP adjuvant paclitaxel study showed Tau-related prognostic signals concordant with our own but this possibility cannot be ruled out in the absence of a comparative study (41) .
In our current study, higher than median p53 protein staining was also found to High Bcl-2 levels were correlated with longer disease-free and overall survival in univariate analysis but this was not confirmed in the multivariate analysis.
In an exploratory subgroup analysis we determined the distribution of the 4 most promising exploratory markers (tau, tubulin III, Ki 67 and P53) in the molecular subgroups previously described (triple negative, Her 2, luminal A and luminal B) (Supplemental Table 1 ). These data show that the distribution of each of the markers is significantly different between subgroups, in particular with low tau and high tubulin III expression in the triple negative subgroup and high tau and low tubulin III expression in the luminal A subgroup.
Strengths of this study include the assessment of novel molecular markers within a mature randomized study, the large number of samples studied, the high proportion of study subjects for whom tissue was available for analysis (91%), and the prospectively defined nature of this analysis. Limitations of the study include the use Table 2 . Expression levels of exploratory biological parameters
The ranges for all exploratory markers was 0-100%.
Research. Table 5 . Results of univariate analysis: correlations with overall survival HR: hazards ratio; 95%CI: 95% confidence interval.
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